Hutchison China MediTech has unveiled top-line results from FRESCO, its Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer (“CRC”) in China, who failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan
La Jolla Pharmaceutical’s catecholamine resistant hypotension (CRH) drug, LJPC-501 (angiotensin II) has met its primary endpoint in a phase 3 study.
ProMetic Life Sciences has revealed positive results for PBI-4050 from its open label Phase 2 clinical trial in idiopathic pulmonary fibrosis ("IPF") patients.
ImmusanT has completed a phase 1b clinical trial evaluating the safety and tolerability of Nexvax2 in celiac disease.
Biopharmaceutical firm hVIVO PLC on Tuesday said the US National Institute of Health has initiated a phase one clinical trial of AGS-v, an investigational vaccine for mosquito-borne diseases like malaria and Zika.
ViiV Healthcare has announced positive results from its phase 3 program assessing the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir and rilpivirine.
Immunomedics has signed a development and licensing agreement worth up to $2bn with Seattle Genetics for its experimental cancer drug.
Preliminary results from a proof-of-concept (POC) study evaluating Viking Therapeutics' VK2809 in an in vivo model of a rare orphan disorder, dubbed glycogen storage disease Ia (GSD 1a), demonstrated an encouraging effect.
GW Pharmaceuticals has unveiled positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme, or GBM.
Immunovaccine has announced that the UHN’s Princess Margaret Cancer Centre (PM) will carry out a Phase 2 clinical trial to assess the use of a combination of immunotherapies from Immunovaccine and Merck.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.